8-K Announcements
6Material company update
May 12, 2026·SEC
Material company update
May 12, 2026·SEC
Material company update
May 7, 2026·SEC
Astrana Health, Inc.(ASTH)Earnings, Financials & Key Ratios
ASTH•NASDAQ
$46.91
102.0× P/E·Price updated Jul 6, 2026
AboutAstrana Health, Inc., Inc., a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. The company's physician network consists of primary care physicians, specialist physicians and extenders, and hospitalists. It serves patients, primarily covered by private or public insurance, such as Medicare, Medicaid, and health maintenance organization plans; and non-insured patients. The company was formerly known as Apollo Medical Holdings, Inc. and changed its name to Astrana Health, Inc. in February 2024. Astrana Health, Inc. was incorporated in 1985 and is headquartered in Alhambra, California.Show more
- Revenue$3.18B+56.4%
- EBITDA$124M+6.0%
- Net Income$22M-47.9%
- EPS (Diluted)0.46-48.9%
- Gross Margin9.3%-30.3%
- EBITDA Margin3.91%-32.2%
- Operating Margin2.47%-43.8%
- Net Margin0.71%-66.7%
- ROE4.19%-55.1%
ASTH Price & Volume
Astrana Health, Inc. (ASTH) stock price & volume — 10-year historical chart
Loading chart...
Aggressive Inorganic Growth Pressures Operating Margin Stability
Investment Thesis • Updated 2026Q1
VerdictNeutral
Growth:Accelerating
Profitability:Strained
Financial:Mixed
Cash Flow:Mixed
Primary Risk:Margin compression from scaling
Key Thesis Takeaways
- Astrana Health is pursuing an aggressive inorganic growth strategy, evidenced by a $548.6 million acquisition in 2025Q3, which has successfully scaled revenue by 55.6% year-over-year as of 2026Q1.
- However, this expansion has resulted in significant margin compression, with gross margins falling from 17.0% in 2024Q1 to 9.4% in 2026Q1, and a substantial increase in financial leverage.
- Investors should monitor whether the company can achieve operational synergies to improve its thin 1.5% net margin while managing a debt-to-equity ratio that has climbed to 1.84.
Verdict Logic
while revenue growth is accelerating at 55.6%, the company's thin 1.5% net margin and high debt-to-equity ratio of 1.84 warrant caution regarding long-term profitability.
ASTH Growth Metrics
Astrana Health, Inc. (ASTH) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years53.76%
3 Years40.62%
TTM56.69%
Profit CAGR
10 Years-
5 Years-
3 Years-20.75%
TTM-13.64%
EPS CAGR
10 Years-
5 Years-14.55%
3 Years-22.55%
TTM-16.78%
Return on Capital
10 Years4.87%
5 Years10.87%
3 Years9.2%
Last Year6.06%
ASTH Recent Earnings
Astrana Health, Inc. (ASTH) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 7/12 qtrs (58%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.74+155.2%
$0.29
Rev
$965M+1.7%
$949M
Q2 2026
Mar 2, 2026Metric
Actual
Est
EPS
$0.54+260.0%
$0.15
Rev
$951M+2.2%
$930M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.01-97.9%
$0.47
Rev
$956M+2.7%
$930M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.19-47.2%
$0.36
Rev
$655M-30.6%
$944M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.74vs $0.29+155.2% | $965Mvs $949M+1.7% |
| Q2 2026 | Mar 2, 2026 | $0.54vs $0.15+260.0% | $951Mvs $930M+2.2% |
| Q4 2025 | Nov 6, 2025 | $0.01vs $0.47-97.9% | $956Mvs $930M+2.7% |
| Q3 2025 | Aug 7, 2025 | $0.19vs $0.36-47.2% | $655Mvs $944M-30.6% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Astrana Health, Inc. (ASTH)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $46.91 | $2.33B | 101.98 | 56.39% | 0.71% | 4.19% | 0.34% | |
| $24.56 | $5.02B | -6637.84 | 46.06% | 0.47% | 11.5% | — | |
| $5.06 | $2.62B | -29.76 | 40.34% | -2.58% | -17.08% | — | |
| $31.44 | $8.15B | -18.60 | 27.5% | -0.3% | -3.26% | — | |
| $232.69 | $163.03B | 167.40 | 35.82% | 12.31% | 3.49% | — | |
| $107.60 | $1.8B | -4.39 | -2.11% | -6.42% | -146.01% | — |
Compare ASTH vs Peers
Astrana Health, Inc. (ASTH) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ASTH SEC Filings & Documents
Astrana Health, Inc. (ASTH) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when ASTH posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ASTH Frequently Asked Questions
Astrana Health, Inc. (ASTH) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Astrana Health, Inc.'s revenue?
Astrana Health, Inc. (ASTH) reported $3.53B in revenue for fiscal year 2025. This represents a 7906% increase from $44.0M in 2015.
How fast is Astrana Health, Inc. growing?
Astrana Health, Inc. (ASTH) grew revenue by 56.4% over the past year. This is strong growth.
Is ASTH profitable?
Yes, Astrana Health, Inc. (ASTH) is profitable, generating $30.2M in net income for fiscal year 2025 (0.7% net margin).
Dividend & Returns
Does ASTH pay dividends?
Yes, Astrana Health, Inc. (ASTH) pays a dividend with a yield of 0.34%. This makes it attractive for income-focused investors.
What is ASTH's return on equity?
Astrana Health, Inc. (ASTH) has a return on equity (ROE) of 4.2%. This is below average, suggesting room for improvement.
What is Astrana Health, Inc.'s free cash flow?
Astrana Health, Inc. (ASTH) generated $155.0M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.